BeOne Medicines AG (ONC)

Market Cap	34.54B +35.7%
Revenue (ttm)	5.34B +40.2%
Net Income	286.93M
EPS	2.47
Shares Out	110.90M
PE Ratio	126.44
Forward PE	55.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,275
Open	312.86
Previous Close	312.31
Day's Range	310.86 - 314.91
52-Week Range	n/a
Beta	0.54
Analysts	Strong Buy
Price Target	380.45 (+22.17%)
Earnings Date	May 6, 2026

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 12,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://beonemedicines.com

Analyst Summary

According to 11 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price target is $380.45, which is an increase of 22.17% from the latest price.

Price Target

$380.45

(22.17% upside)

Analyst Consensus: Strong Buy